Elsevier

Gynecologic Oncology

Volume 99, Issue 3, December 2005, Pages 640-644
Gynecologic Oncology

Preoperative chemoradiation for locally advanced carcinoma of the vulva

https://doi.org/10.1016/j.ygyno.2005.07.126Get rights and content

Abstract

Objective.

A twice daily (BID) radiation treatment schedule (interval of 4–6 h) delivered concurrent with chemotherapy for advanced or critically located carcinoma of the vulva was modeled on the schema developed by the Gynecology Oncology Group (GOG). Inguinal nodes were included in the treatment fields even if clinically negative. This review analyzed the outcomes using this approach.

Methods.

A retrospective review was conducted of the records of 18 patients with vulvar cancer. Patients were treated with a modified GOG schema using 5-fluorouracil (5FU) and cisplatin with BID radiation treatments during the first and last weeks of treatment and seven daily radiation treatments in between. The regional nodes and primary tumor were prescribed 44.6 Gy. Resection of the primary tumor bed and inguinal dissection was planned at 4–6 weeks post-treatment. Clinical and pathological responses as well as locoregional control and toxicity were assessed.

Results.

All patients responded. There were 13/18 complete clinical responses (cCR), of whom 12 remained NED at 25 months. Of the five partial clinical response (cPR) patients, two have suffered local recurrences, despite surgical resection in one and electron boost in the other. All patients developed a desquamative perineal skin reaction necessitating a mean treatment break of 15 days. No severe hematological toxicity was encountered, and only one patient had grade 3 small bowel toxicity. One patient required surgical debridement for groin wound breakdown.

Conclusion.

The use of BID chemoradiation resulted in complete or partial responses in all cases. Post-treatment groin dissection can be performed without significant post-operative complications.

Introduction

Carcinoma of the vulva is an unusual gynecological malignancy accounting for only 5% of gynecological cancers per year with 3870 cases estimated to occur in 2005 [1]. For many years, the treatment was entirely surgical, often involving large en bloc resections with significant morbidity. Preoperative radiation has been used to decrease the extent of surgery required to clear advanced tumors or those located near critical midline structures. More recently, chemotherapy has been utilized to maximize the response to preoperative radiation therapy. The Gynecological Oncology Group (GOG) performed a prospective study to assess preoperative chemoradiation in patients with locally advanced disease [2], [3]. The first publication described the outcomes of patients with T3 or T4 primaries, irrespective of groin nodal status. Split course chemoradiation using a BID radiation schedule combined with 5-fluorouracil and cisplatin during the first and final weeks of radiotherapy resulted high rates of resectability and local control in these very unfavorable patients [2]. The second publication was limited to patients with N2/3 nodal disease, most of whom had extensive primary tumors [3]. Of the forty evaluable patients, thirty-eight became resectable, and 15/37 had a pathological complete response. The morbidity of treatment, including post-treatment groin dissection complications, was acceptable. Given this high rate of resectability and local control in patients with locally advanced nodal disease, the authors concluded that patients with less advanced disease should be considered for preoperative chemoradiation. This was the policy adopted at our institution. This study reviews the outcomes using a modified GOG treatment technique.

Section snippets

Materials and methods

A retrospective review of 18 records of patients who underwent preoperative chemoradiation for squamous cell carcinoma of the vulva was undertaken with IRB approval (IRB-21-053). All patients were assessed jointly with a gynecological oncologist and staged using the FIGO clinical staging system without histological confirmation of positive groin nodes [4]. All patients received treatment at the Magee Women's Hospital of the University of Pittsburgh Medical Center. Patients were offered

Results

Seventeen patients were treated with preoperative chemoradiotherapy, and one received preoperative radiotherapy alone because of refusal to receive chemotherapy. Chemotherapy was delivered as specified on the GOG study during the first and last weeks of the course of external beam treatment (Fig. 1). All patients received treatment to the primary tumor and regional nodes except for one patient (treated to primary alone) who underwent a negative pretreatment groin dissection.

The patient

Discussion

Organ preservation and minimization of disfiguring surgery have been achieved in multiple tumor sites with the use of chemoradiation to downstage tumors preoperatively. Combined modality therapy for vulvar cancer has become an established treatment for advanced vulvar cancer or in cases in which the tumor is located in close proximity to the urethra or anus [2], [3], [5], [6], [7], [8]. Because this is an unusual gynecological malignancy, there are no large-scale trials available to document

Conclusion

Neoadjuvant chemoradiation for vulvar cancer is an excellent treatment option for patients with bulky or critically located tumors, resulting in a complete response in the majority of cases. The treatment is well tolerated, even in an elderly population. Up front treatment of both the primary tumor and regional nodes can be given with chemosensitization without excessive toxicity. The role of intensity-modulated radiation therapy technique appears to be feasible in the small subgroup of

Cited by (55)

  • Locally advanced squamous cell carcinoma of the vulva: A challenging question for gynecologic oncologists

    2020, Gynecologic Oncology
    Citation Excerpt :

    The clinical complete response rates following CCRT range from 25.0. % to 72.2% [34–47]. However, disease subsequently relapses in up to one third of the complete responders.

  • Neoadjuvant and definitive chemotherapy or chemoradiation for stage III and IV vulvar cancer: A pooled Reanalysis

    2017, European Journal of Obstetrics and Gynecology and Reproductive Biology
View all citing articles on Scopus
View full text